Pandom Dsr

# Pandom dsr ## Overview - **Classification**: **Pantoprazole** (Proton Pump Inhibitor - PPI), **Domperidone** (Dopamine D2 receptor antagonist, Prokinetic) - **Mechanism**: Pantoprazole irreversibly blocks the H+/K+ ATPase proton pump in gastric parietal cells, reducing acid secretion. Domperidone blocks peripheral dopamine D2 receptors in the chemoreceptor trigger zone and gut, enhancing gastric motility and antiemetic effects. ## Primary Indications 1. **Gastroesophageal Reflux Disease (GERD)** with associated nausea, vomiting, or motility disorders. 2. **Dyspepsia** (non-ulcer) characterized by epigastric pain, bloating, or early satiety, often with nausea. 3. **Reflux Esophagitis** associated with delayed gastric emptying. ## Adult Dosing ### Standard Dosing **GERD/Dyspepsia with Motility Issues** - **Dose**: **Pantoprazole 40 mg** and **Domperidone 30 mg** (sustained-release formulation) - **Frequency**: Once daily - **Route**: Oral - **Timing**: Typically 30 minutes before breakfast - **Duration**: Usually 4-8 weeks, or as clinically indicated. ### Dose Adjustments - **Renal Impairment**: - **Domperidone**: No adjustment for mild; **contraindicated** in moderate-to-severe (CrCl < 30 mL/min). - **Pantoprazole**: No dose adjustment necessary. - **Hepatic Impairment**: - **Domperidone**: **Contraindicated** in moderate to severe hepatic impairment (Child-Pugh B and C). - **Pantoprazole**: Reduce dose to **20 mg** once daily in severe hepatic impairment (Child-Pugh C). - **Elderly Patients**: - Use with caution, especially with Domperidone due to increased risk of cardiac adverse events (QT prolongation, arrhythmias). - Consider lower doses or alternative agents if cardiac risk factors are present. ## Pediatric Dosing **Note**: The combination product "Pandom dsr" is generally **NOT recommended for pediatric use** due to the significant cardiac risks associated with Domperidone, especially in younger children, and the availability of safer alternative treatments. ### Neonates (0-28 days) - **Not recommended**: The combination product is contraindicated due to Domperidone's risk of QT prolongation and potential for sudden cardiac death. ### Infants (1-12 months) - **Not recommended**: As above, the combination product is contraindicated due to Domperidone's safety profile in this age group. ### Children (1-12 years) - **Not recommended**: Avoid use due to Domperidone-related cardiac risks (QT prolongation, arrhythmias). Individual components may be used separately if indicated and carefully considered by a specialist. ### Adolescents (13-18 years) - **Use with extreme caution**: Generally, the combination product should be avoided. - If used in rare, compelling circumstances under specialist supervision, apply adult dose considerations. - **Maximum**: Refer to adult maximum doses; strict cardiac monitoring is essential. - **Special Notes**: A thorough cardiovascular assessment is required. Risks often outweigh benefits. ## Safety Information ### Contraindications - **Absolute**: Hypersensitivity to pantoprazole, domperidone, or excipients. - **Absolute**: Gastrointestinal hemorrhage, mechanical obstruction, or perforation. - **Absolute**: Prolactinoma. - **Absolute**: Moderate to severe hepatic impairment (Child-Pugh B or C) for Domperidone. - **Absolute**: Known QT interval prolongation or significant cardiac disease (e.g., heart failure). - **Absolute**: Co-administration with potent CYP3A4 inhibitors (e.g., ketoconazole, erythromycin). - **Absolute**: Co-administration with other QT-prolonging drugs (e.g., certain antiarrhythmics, antipsychotics). ### Common Adverse Effects - **Very Common (>10%)**: Headache (Domperidone), Dry mouth (Domperidone) - **Common (1-10%)**: Nausea, vomiting, diarrhea, abdominal pain, flatulence (Pantoprazole). Dizziness (Domperidone). - **Serious but Rare**: - **Domperidone**: QT prolongation, Torsades de Pointes, sudden cardiac death, extrapyramidal symptoms, hyperprolactinemia. - **Pantoprazole**: *Clostridioides difficile* infection, acute interstitial nephritis, bone fractures, hypomagnesemia, Vitamin B12 deficiency (long-term use). ### Key Drug Interactions - **Potent CYP3A4 inhibitors (e.g., ketoconazole, erythromycin)**: Significantly increase Domperidone levels, increasing cardiac risk. **Concurrent use is contraindicated.** - **QT-prolonging drugs (e.g., Class IA and III antiarrhythmics, some antipsychotics, macrolides)**: Additive risk of QT prolongation with Domperidone. **Concurrent use is contraindicated.** - **Drugs requiring acidic pH for absorption (e.g., atazanavir, nelfinavir, itraconazole)**: Pantoprazole significantly reduces absorption. Avoid concurrent use or monitor closely. - **Warfarin**: May increase INR. Monitor prothrombin time/INR. - **Methotrexate**: May increase methotrexate levels, especially high-dose. Consider temporary PPI withdrawal. ## Monitoring & Follow-up - **Before Treatment**: Assess cardiac history and current medications for QT-prolonging potential. Baseline electrolytes if risk for imbalance. - **During Treatment**: Monitor for symptom resolution. - **Clinical Signs**: Watch for signs of cardiac arrhythmias (palpitations, syncope), GI bleeding, or unusual muscle movements (Domperidone). ## Clinical Pearls - 💡 **Timing is Key**: Take **30 minutes before the first meal** of the day for optimal effect. - 💡 **Cardiac Safety**: Domperidone carries a **Black Box Warning (in some regions)** for serious cardiac events. Carefully weigh risks vs. benefits, especially in patients with pre-existing heart conditions or electrolyte imbalances. - 💡 **Short-term Use**: Use the lowest effective dose for the **shortest possible duration** (typically <1 week for Domperidone component) to minimize risks. - 💡 **Calcium & B12**: For long-term PPI use (Pantoprazole), consider monitoring calcium and Vitamin B12 levels and potentially supplementing. > **⚠️ Important**: This information is for educational purposes only. Always consult current prescribing information, local guidelines, and clinical judgment before prescribing.